.png)
Editor: Anthony Tong, World Salon Research Analyst
The World Salon is delighted to launch the "Daily Digest", where we handpick must-know news of each sector for our subscribers. In today's fast-paced world, staying informed is paramount, but it is easy to get overwhelmed by the numerous newsletters that bombards your inbox each day. Our solution offers a concise yet comprehensive overview of the most significant developments impacting various industries.
Gemini produces controversial responses to ethical, historical, and philosophical questions which angers its users. This reflects how Google was hesitant about publicizing Chatbot technology, but was pushed to do so when OpenAI's ChatGPT revolutionized the AI market. Google Publicity tried to deal with ethical questions by undermining their own chatbot's accuracy and focus on its creativity. Demis Hassabis, head of Google DeepMind, said on Monday that the company planned to restore Gemini’s ability to generate images of people in the next couple of weeks. (CNBC)
Newsmast introduces a novel approach to decentralized social media by integrating content from two servers into one interface through its updated Mastodon mobile app. This unique model allows Mastodon users to connect with topic-based timelines called Communities, addressing the challenge of content curation in decentralized networks. Backed by the Newsmast Foundation, the app aims to provide an ad-free alternative to mainstream social media platforms like Twitter where users can explore new topics and foster meaningful conversations. (TechCrunch)
After last month's Boeing incident, the FAA intervened and began an investigation on safety concerns of Boeing. As the public demands total evaluation of Boeing's safety protocols, the investigation brought concerning news that Boeing senior managers are "disconnected" from its employees. The report understands that Boeing has "a lack of awareness of safety-related metrics at all levels of the organization." Boeing responded that they would proceed with measures that improve the safety culture. (Reuters)
A new study found out that while doctors knew about Oral rehydration salts to treat diarrhea, they aren't prescribing them enough. The one dominant reason for not prescribing oral rehydration salts: nearly half of the cases of failure to prescribe were because the health-care provider assumed the parents would not be satisfied with ORS. Many patients also choose to go to pharmacy instead of hospitals, which over-prescribe antibiotics instead of ORS, the easier, simpler and cheaper prescription. (NPR)
In the beginning of 2024, dozens of biotech companies went public, signaling the return of biotech companies in top-notch research. Cutting federal interest rates certainly helped their financial situation. CG Oncology, which has a bladder-cancer treatment in late-stage trials, raised about $400 million in net proceeds during its IPO last month. The first biotech to go public in 2024, the company raised more than it had expected. ArriVent BioPharma, a biotech with a lung-cancer drug in the final clinical trial phase, raised about $180 million in net proceeds during its market debut shortly after. (WSJ)
After a series of setbacks, AstraZeneca has relinquished rights to Roxadustat in the U.S., but retained interest in the HIF-PH inhibitor in China and South Korea, where the drug is branded as "Evrenzo". Despite Roxadustat's challenges, AstraZeneca's former partner FibroGen remains optimistic, looking towards other potential partnerships and focusing on their lead candidate, Pamrevlumab, with phase 3 trial results expected in the second quarter for locally advanced pancreatic cancer. (Fierce Pharma)
Ether becomes the next major target to launch Exchange-Traded funds for Wall Street firms after bitcoin. BlackRock, Fidelity among others are filing applications to the SEC, which are expected to respond either way by the end of May. One potential hurdle was the approval of crypto staking, which the SEC understands as unregistered security. (WSJ)
When the world gets back onto its feet after COVID, Zoom experiences winter. Nevertheless, recently the market saw a stock price uptick when Zoom announced its forecasted revenue increase in the next fiscal year. The company projected $4.6 billion in revenue for the current fiscal year, which would amount to a 2% growth. (WSJ)
China's EV champion BYD cuts its prices for gas-fueled cars to further compress the margins of automobile market against mainly the foreign gas-fuel car providers. The models in question are plug-in hybrids, which are usually cheaper than pure EVs due to smaller batteries. BYD seeks to increase its exports and its domestic premium models to gain advantage over smaller EV companies in China. (WSJ)
